• Comprehensive review of operations, corporate actions, financial position, governance, and disclosure practices during suspension
• Commitment to high standards of corporate governance, transparent communication, and full compliance with ASX and Corporations Act obligations
• Disciplined and sustainable growth strategy upon reinstatement to quotation

Epsilon Healthcare Limited (ASX: EPN) has provided a comprehensive pre-reinstatement disclosure to the Australian Securities Exchange (ASX), detailing the company's operations, corporate actions, financial position, governance arrangements, and disclosure practices during the period of suspension. The company has undertaken a thorough internal review and aims to provide the market with full transparency and a clear understanding of its position as it moves towards the reinstatement of trading in its securities. Epsilon Healthcare remains committed to maintaining high standards of corporate governance, transparent communication with shareholders, and full compliance with its obligations under the ASX Listing Rules and the Corporations Act. The company's immediate and medium-term objectives reflect a strong commitment to regulatory compliance, market leadership, product and service innovation, and the creation of sustainable long-term shareholder value. Key strategic priorities include strengthening operational stability and market confidence, accelerating growth in its contract development and manufacturing operations, expanding clinical and patient services through digital innovation, and a continued focus on innovation, diversification, and long-term shareholder value creation.

The company confirms it will have sufficient working capital at the time of reinstatement to carry out its stated objectives, without the need to raise further capital, for at least the next 12 months. The company has secured a $2 million promissory note from the Group Chief Executive Officer and Managing Director, extended the repayment of its secured borrowings to June 2027, and deferred $808,000 of director-related liabilities without solvency impact.

Epsilon Healthcare remains firmly committed to developing innovative products and services, leveraging its GMP infrastructure and regulatory credentials to enable scalable growth, identifying strategic opportunities that diversify revenue streams and enhance operational resilience, and executing a disciplined growth strategy designed to deliver sustained shareholder value.